Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Organon (OGN)
NYSE:OGN
Organon (OGN) Stock Price & Analysis
742 Followers
OGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.53 - $22.54
Previous Close$20.57
Volume780.87K
Average Volume (3M)2.06M
Market Cap
$5.39B
Enterprise Value$13.43B
Total Cash (Recent Filing)$575.00M
Total Debt (Recent Filing)$8.71B
Price to Earnings (P/E)5.0
Beta1.01
Next Earnings
Aug 07, 2024EPS Estimate
$1.17Last Dividend Ex-Date
May 10, 2024Dividend Yield5.34%
Share Statistics
EPS (TTM)4.08
Shares Outstanding257,170,727
10 Day Avg. Volume1,569,963
30 Day Avg. Volume2,062,748
Standard Deviation0.13
R-Squared0.11
Alpha-0.00698
Financial Highlights & Ratios
Price to Book (P/B)-1.02
Price to Sales (P/S)3.26
Price to Cash Flow (P/CF)17.80
P/FCF Ratio14.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.12
Enterprise Value/Gross Profit3.58
Enterprise Value/Ebitda15.28
Forecast
1Y Price Target
$23.00Price Target Upside9.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Organon News
PremiumCompany Announcements
Organon Q1 2024 Financial Results Presentation Update
PremiumCompany Announcements
Organon & Co. Is Worried About This – Should You Be Worried Too?
Bulls Say, Bears Say
Bulls Say
Financial PerformanceA solid start to the year with first quarter results coming out ahead of expectations on both the top and bottom lines.
Financial StrategyThe capital allocation strategy is prudently balanced, with commitments to dividends and a target to reduce leverage significantly.
Market Share And Product PerformanceHeadlining components of the portfolio, including Nexplanon, performed well with a significant increase in the US market.
Bears Say
Research And DevelopmentReductions in research and development spending could delay the acquisition of assets necessary to offset the loss of exclusivity for Nexplanon in the 2025-27 timeframe.
Revenue ForecastAnalysts have lowered revenue estimates for Nexplanon and Hadlima, indicating potential challenges ahead for the company's financial performance.
Stock RatingThe stock has been reiterated with an UNDERPERFORM rating, suggesting that it may not keep pace with the broader market or its sector peers.
---
Ownership Overview
0.20% Insiders
33.71% Mutual Funds
45.37% Other Institutional Investors
20.71% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OGN FAQ
What was Organon’s price range in the past 12 months?
Organon lowest stock price was $10.53 and its highest was $22.54 in the past 12 months.
What is Organon’s market cap?
Currently, no data Available
When is Organon’s upcoming earnings report date?
Organon’s upcoming earnings report date is Aug 07, 2024 which is in 69 days.
How were Organon’s earnings last quarter?
Organon released its earnings results on May 02, 2024. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $0.978 by $0.242.
Is Organon overvalued?
According to Wall Street analysts Organon’s price is currently Undervalued.
Does Organon pay dividends?
Organon pays a Quarterly dividend of $0.28 which represents an annual dividend yield of 5.34%. See more information on Organon dividends here
What is Organon’s EPS estimate?
Organon’s EPS estimate is $1.17.
How many shares outstanding does Organon have?
Organon has 257,170,720 shares outstanding.
What happened to Organon’s price movement after its last earnings report?
Organon reported an EPS of $1.22 in its last earnings report, beating expectations of $0.978. Following the earnings report the stock price went up 3.554%.
Which hedge fund is a major shareholder of Organon?
Among the largest hedge funds holding Organon’s share is Slate Path Capital LP. It holds Organon’s shares valued at 97M.
---
Organon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.00 (9.84% Upside)
$23.00 (9.84% Upside)
Blogger Sentiment
Bullish
OGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 4.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.48%
Trailing 12-Months
Company Description
Organon
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
---
OGN Company Deck
---
OGN Earnings Call
Q1 2024
0:00 / 0:00
---
OGN Stock 12 Month Forecast
Average Price Target
$23.00
▲(9.84% Upside)
Technical Analysis
Best Analysts Covering OGN
1 Year
1 Year Success Rate
5/7 ratings generated profit
1 Year Average Return
+18.16%
assigned a buy rating last month
Copying David Amsellem's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +18.16% per trade.
---